Redeye provides an initial take following the release of Corline’s Q3 2025 report.
* Q3 adj. EBITDA 11% below FactSet consensus * Raises operating cash flow guidance * Restatements yi...
Lipum and Flerie have agreed to merge in a transaction that will see Lipum absorbed into Flerie in e...
Redeye returns with an update following Elicera’s Q3 earnings release.
Som förväntat inga större nyheter. Möjlig liten försening av finansieringspaketet, vägs upp av möjli...
Redeye comments on Friday’s press release from Enviro, stating that the timeline for the Uddevalla p...
Redeye comments on Friday’s press release from Waystream, stating it has signed a strategic partners...
Byggparten Gruppen visar fortsatt stark ordertillväxt – orderingången ökade 93 procent till 1 559 mk...
Thunderful enters 2026–2027 with a release pipeline that shows potential, albeit with some uncertain...
Alzecure drar i gång en avslutande fas 1-studie med ACD-856 för att dokumentera högre doser jämfört ...
Redeye gives a short comment on the news that the FDA has accepted Ascelia’s NDA application for Orv...
Redeye provides a research update following Dala Energi’s Q3 report, published last Friday.
Redeye updates its estimates and valuation following Navigo releasing its Q3 2025 report.
Smart Eye’s Q3 report tracked closely with our expectations, with Automotive once again acting as th...
Redeye provides an update following Paxman’s Q3 2025 report.
Nettoomsättningen för Q3’25 uppgick till 7,9 MEURO (9,7), motsvarande en minskning om 17,9 % y-o-y.
Redeye gives an initial comment on the top-line readout from the ReTRIACt study with Emcitate.
Redeye notes improved cost control in the preliminary Q2 figures, and sales in line with our lowered...
VBG Group redovisade en omsättningsökning på 7,5 % till 1 362 MSEK under Q3 2025, varav 6,3 % var or...
